Maxim Group Maintains Buy on Definium Therapeutics, Raises Price Target to $55
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. DFTX | 0.00 |
Maxim Group maintains Definium Therapeutics (NASDAQ:
DFTX) with a Buy and raises the price target from $50 to $55.
